UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 16, 2014
INSULET CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware | 001-33462 | 04-3523891 | ||
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
600 Technology Park
Suite 200
Billerica, Massachusetts 01821
(Address of Principal Executive Offices, including Zip Code)
Registrants telephone number, including area code: (978) 600-7000
9 Oak Park Drive
Bedford, Massachusetts 01730
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
On September 16, 2014, Duane DeSisto announced his retirement as the President and Chief Executive Officer and as a Director of Insulet Corporation (the Company). On such date, Mr. DeSisto and the Company entered into a Retirement Agreement (the Retirement Agreement).
Pursuant to the Retirement Agreement, Mr. DeSisto will receive the following principal benefits:
| Severance pursuant to the Companys Amended and Restated Executive Severance Plan (the Company Severance Plan), consisting of the continuation for 24 months of Mr. DeSistos base salary; |
| Continuation of health, dental and life insurance pursuant to the Company Severance Plan; |
| The immediate vesting in full of all of the stock options and time-based restricted stock units (RSUs) issued by the Company to Mr. DeSisto; |
| The right to exercise all of his outstanding stock options for one year following his retirement; and |
| The vesting in full of all performance-based RSUs issued by the Company to Mr. DeSisto if and to the extent earned. |
The Retirement Agreement contains restrictive covenants applicable to Mr. DeSisto regarding noncompetition, nonsolicitation, nondisparagement and nondisclosure of confidential information and includes a customary release in favor of the Company.
The foregoing description of the Retirement Agreement is qualified in its entirety by the full text of the Retirement Agreement filed herewith as Exhibit 10.1 and incorporated herein by reference.
Item 5.02. Departures of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements with Certain Officers.
Retirement of Duane DeSisto as President, Chief Executive Officer and Director
On September 16, 2014, Duane DeSisto retired as the President and Chief Executive Officer of the Company and as a member of the Companys Board of Directors (the Board). Mr. DeSistos departure is not due to a disagreement with the Company on any matter relating to the Companys operations, policies, or practices. In connection with his retirement as President, Chief Executive Officer and Director, the Company entered into the Retirement Agreement, as more particularly described in Item 1.01 of this Report, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.
Appointment of Patrick J. Sullivan as President, Chief Executive Officer and Director
Effective September 16, 2014, the Board appointed Patrick J. Sullivan as President and Chief Executive Officer of the Company. Mr. Sullivan was also appointed to serve as a Class III Director with a term expiring at the 2016 annual meeting of stockholders. Mr. Sullivan, age 62, previously served as the President and Chief Executive Officer of Cytyc Corporation from 1994 to 2007, Executive Chair of Hologic Corporation from 2007 to 2008, Chief Executive Officer of Constitution Medical Investors from 2008 to 2013 and Managing Director of Aton Partners since 2013. Mr. Sullivan also serves as a director of PerkinElmer, Inc. Mr. Sullivan received a B.S. degree from the United States Naval Academy and a M.B.A. from the Harvard Business School.
There are no relationships or related party transactions involving Mr. Sullivan or any member of his immediate family required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Pursuant to an Employment Agreement dated as of September 16, 2014 (the Employment Agreement), the Company has agreed to pay Mr. Sullivan an annual base salary of $650,000, and Mr. Sullivan will be eligible to participate in the Companys Executive Incentive Compensation Program with a target bonus of 100% of his base salary. In connection with the commencement of Mr. Sullivans employment, the Company has agreed to grant him on October 1, 2014, as an employment inducement award, an option to purchase that number of shares of the Companys common stock equal to $11,000,000 divided by 59.83% of such options exercise price. The option will have an exercise price equal to the fair market value of the Companys common stock as of the date of grant. In
2
addition, 25% of the option shares will vest on December 31, 2014, with the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters. Mr. Sullivan will also be entitled to termination benefits as set forth in the Employment Agreement and the Companys Amended and Restated Executive Severance Plan, as modified by the Employment Agreement with respect to Mr. Sullivan. A copy of the Employment Agreement is attached hereto as Exhibit 10.2 and is incorporated herein by reference. The foregoing summary of the Employment Agreement is qualified in its entirety by reference to the text of the Employment Agreement.
On September 16, 2014, the Company issued a press release regarding the retirement of Mr. DeSisto and the appointment of Mr. Sullivan. A copy of the press release is attached as Exhibit 99.1 hereto.
Item 9.01. Financial Statements and Exhibits.
(d) | Exhibits. |
Exhibit No. |
Description |
|
10.1 | Retirement Agreement by and between Insulet Corporation and Duane DeSisto dated September 16, 2014 | |
10.2 | Employment Agreement by and between Insulet Corporation and Patrick J. Sullivan dated September 16, 2014 | |
99.1 | Press Release dated September 16, 2014 |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned thereunto duly authorized.
INSULET CORPORATION | ||||||
September 16, 2014 | By: |
/s/ Daniel Levangie |
||||
Lead Director |
4
Exhibit 10.1
RETIREMENT AGREEMENT
This Retirement Agreement ( Retirement Agreement or Agreement ) is made between Duane DeSisto ( Executive ) and Insulet Corporation ( Insulet or the Company ,) (together, the Parties ).
WHEREAS , Executive is retiring and resigning from his employment with the Company effective, September 17, 2014 (the Retirement Date );
WHEREAS , this Retirement Agreement fully supersedes any prior agreements and understandings related to Executives employment at Insulet;
WHEREAS , a retirement and voluntary resignation is not included in the definition of a Terminating Event under Section 2(h)(i) of the Insulet Corporation Amended and Restated Executive Severance Plan adopted as of May 8, 2008, amended and restated as of November 14, 2009 and December, 2012 (the Severance Plan ) (unless otherwise specifically defined herein, capitalized terms shall have the same meaning as the terms defined in the Severance Plan);
WHEREAS , in the interest of an amicable departure and in recognition of Executives substantial services and contributions to the Company, and in exchange for, among other things, Executive entering into and complying with this Retirement Agreement, the Company shall treat the ending of Executives employment as a Terminating Event under Section 2(h)(i) of the Severance Plan (prior to a Change in Control) pursuant to which Executive is eligible to receive certain termination benefits consistent with the Severance Plan, and, in addition, shall provide the Executive with certain supplemental severance benefits, all as described in this Agreement (collectively the Severance Benefits );
WHEREAS , the payments set forth in this Retirement Agreement are the exclusive payments, benefits and rights to Executive in connection with the ending of Executives employment within the Company, and by entering into this Retirement Agreement, Executive acknowledges and agrees that he is not entitled to any other severance pay, benefits, equity rights or any other form of compensation or payment including without limitation pursuant to any other agreement, severance plan, program, policy or arrangement, except as otherwise specifically set forth herein.
NOW, THEREFORE , for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:
1. Resignation from Employment, Director and Officer Positions of the Company and its Subsidiaries and Affiliates; Post Employment Consulting . As of the Retirement Date, Executive hereby retires and resigns from his employment with the Company and his positions as a member of the Companys Board of Directors (the Board) and as an officer of the Company, as well as from any other director or officer positions he holds with any of the Companys subsidiaries or entities affiliated with the Company. Executive agrees to execute and deliver any documents reasonably necessary to effectuate such resignations, provided that nothing in any such document is inconsistent with anything set forth in this Agreement. Executive further agrees to provide transitional services to the Company up to one day per week through December 31, 2014, subject to the Parties entering into a mutually agreeable consulting agreement.
2. Final Pay; Expense Reimbursement . On the Companys next regular payroll date following the Retirement Date, the Company shall pay Executive his accrued but unpaid base salary and any accrued but unused vacation based on Executives employment through the Retirement Date. The Executive shall be entitled to be reimbursed for his reasonable business expenses incurred prior to the Retirement Date in connection with his employment subject to the Companys policies and procedures with respect to expense reimbursement.
3. Severance Benefits . Provided Executive enters into and complies with this Agreement, the Company will provide him with the following Severance Benefits:
(a) Salary Continuation: Payment of two times the amount of Executives Base Salary of $500,000.02, less applicable deductions and withholdings, payable in substantially equal installments in accordance with the Companys payroll practice over twenty four (24) months, beginning on the first payroll date that occurs after the Retirement Date, provided this Agreement has become effective ( Salary Continuation Payments );
(b) Benefit Continuation: Payment of Executives (and, as may be applicable, his covered dependents) health, dental and life insurance premiums to the same extent as if Executive had remained an active employee until the end of the twenty four-month period beginning on the Retirement Date, provided Executive elects and remains eligible for COBRA, and, for purposes of life insurance, elects to convert to his benefits under the Companys group life insurance plan to an individual life insurance policy. Notwithstanding anything to the contrary in the previous sentence, however, should Executives eligibility for COBRA end prior to the end of the twenty-four month period beginning on the Retirement Date and Executive is not eligible for health insurance through another employer, and if Executive takes the necessary steps to convert his health insurance policy to an individual policy at the end of such COBRA eligibility period, the Company shall continue payments of the premiums, on an after-tax basis, for Executives and any covered dependents health and dental coverage at the level necessary for Executive to maintain substantially comparable coverage for himself and any covered dependents without increasing his own premium contributions. By signing this Agreement, Executive hereby authorizes the Company to deduct the employee portion of health and dental premiums from the Salary Continuation Payments;
(c) Outplacement: Reimbursement of outplacement services not to exceed $15,000, provided that such expenses are incurred by Executive within twelve months of the Retirement Date and Executive presents the Company with reasonably satisfactory evidence of such expenses, such reimbursement shall be made by the Company within thirty (30) days of the Companys receipt of documentation evidencing such expenses.
(d) Pro-Rata Bonus : Payment of an amount equal to the annual target cash incentive under the Companys 2014 executive bonus program ($450,000), prorated
2
based on the Retirement Date (the 2014 Pro-rata Bonus). The 2014 Pro-Rata Bonus will be paid (less applicable deductions and withholdings) in substantially equal installments in accordance with the Companys payroll practice over twenty four (24) months, beginning on the first payroll date that occurs after the Retirement Date, provided this Agreement has become effective.
(e) Accelerated Vesting of Time-Based Equity Awards and Extension of Exercise Periods: Executives outstanding time-based stock options ( Stock Options ) and time-based restricted stock units ( RSUs ) are listed in Tables A and B below shall become fully vested as of the Retirement Date. Notwithstanding anything to the contrary in the applicable agreement with respect to such Stock Options or the stock incentive plan under which such Stock Options were granted, Executive shall have until the earlier of (i) twelve (12) months following the Retirement Date and (ii) the expiration of the term of such Stock Option to exercise such Stock Options.
(f) Vesting of Performance-Based RSUs: Executives performance based RSUs are listed on Table C below and, to the extent some or all of the RSUs are earned (which will be determined after December 31, 2014 based on the 2014 revenue performance metric set forth in the in the applicable RSU Agreement), they will become fully vested on the date of such determination.
(g) Attorneys Fees: The Company will reimburse Executive for legal fees he expends in connection with this Agreement in an amount up to Twenty Thousand Dollars ($20,000).
4. Equity Interests . Executive holds the equity rights set forth in this Section 4 (the Interests ) and the Parties acknowledge and agree that such Interests are subject to the terms and provisions of the Companys Amended and Restated 2007 Stock Option and Incentive Plan and associated Stock Option agreements and RSU agreements (collectively the Equity Documents ) and constitute all of the ownership or other equity interests of the Company Executive owns, beneficially or of record (other than shares of Common Stock of the Company owned outright and not subject to any equity award terms or vesting conditions).
Table A
Stock Options
Grant Date |
Number of
Option Shares Originally Granted, all of which shall vest as of the Retirement Date |
Option Exercise Price
per Share |
||||||
March 12, 2008 |
50,000 | $ | 15.09 | |||||
March 12, 2008 |
25,000 | $ | 18.75 | |||||
March 1, 2010 |
40,000 | $ | 15.16 | |||||
March 1, 2011 |
40,000 | $ | 17.49 | |||||
April 1, 2012 |
70,000 | $ | 19.14 | |||||
March 1, 2013 |
30,000 | $ | 23.40 | |||||
March 3, 2014 |
29,500 | $ | 47.32 |
3
Table B
Time-based Vesting RSUs
Grant Date |
Number of RSUs granted,
|
|||
April 1, 2012 | 70,000 | |||
March 1, 2013 | 60,000 | |||
March 1, 2013 |
60,000 (Performance-based
RSUs that became time- based on the achievement of certain 2013 performance metrics) |
|||
March 3, 2014 | 44,000 |
Table C
Performance-based Vesting RSUs
Grant Date |
Number of RSUs granted,
|
|||
March 3, 2014 | up to 53,250 |
4
5. Releases
(a) |
By Executive . Executive irrevocably and unconditionally releases and forever discharges the Company, all of its affiliated and related entities, its and their respective predecessors, successors and assigns, its and their respective employee benefit plans and the fiduciaries of such plans, and the current and former officers, directors, stockholders, executives, attorneys, accountants, and agents of each of the foregoing in their official and personal capacities (collectively referred to as the Releases ) generally from all claims, demands, debts, damages and liabilities of every name and nature, known or unknown ( Claims ) that, as of the date when Executive signs this Retirement Agreement, he has, ever had, now claims to have or ever claimed to have had against any or all of the Releasees. This release includes, without implication of limitation, the complete waiver and release of all Claims of or arising in connection with or for: the Severance Plan or any employment agreement with the Company including Claims for breach of express or implied contract; wrongful termination of employment whether in contract or tort; intentional, reckless, or negligent infliction of emotional distress; breach of any express or implied covenant of employment, including the covenant of good faith and fair dealing; interference with contractual or advantageous relations, whether prospective or existing; deceit or misrepresentation; discrimination or retaliation under state, federal, or municipal law, including, without implication of limitation, Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., as amended, the Americans with Disabilities Act, 42 U.S.C. § 12101 et seq.; any other federal, state or local law or regulation prohibiting employment discrimination defamation or damage to reputation; reinstatement; punitive or emotional distress damages; wages, severance pay, vacation pay, including without limitation, Claims under the Massachusetts Wage Act, back or front pay or other forms of compensation; and attorneys fees and costs. Executive understands that this general release of Claims extends to any and all Claims related to Executives employment by the Company (including without limitation, any claims against the Company in respect of any stock-based awards of any kind or alleged promises or assurances of such awards, other than as explicitly set forth in this Agreement) and the ending of his employment, and all Claims in his capacity as a Company stockholder arising up to and through the date that Executive enters into this Retirement Agreement. Executive represents that he has not assigned to any third party and has not filed with any agency or court any Claim released by this Retirement Agreement. Notwithstanding anything above, nothing in this release affects or releases Executives rights under or Claims related to this Retirement Agreement or the Equity Documents, nor any rights or Claims of indemnification as an officer and/or director of the Company for his service to the Company prior to the Retirement Date that he has or may have under the Companys articles of incorporation, by-laws, insurance and/or indemnification policies or agreements |
5
and/or otherwise under law, and nothing shall be construed as releasing any claims Executive may have for workers compensation benefits, vested pension or 401(K) benefits, unemployment benefits, benefits under COBRA, or claims to enforce this Agreement. |
(b) | By the Company . The Company hereby releases and forever discharges Executive generally from all known, or reasonably susceptible of being known, claims, demands, debts, damages and liabilities of every name and nature ( Claims ) that, as of the date when the Company signs this Retirement Agreement, the Company has, ever had, now claims to have or ever claimed to have had against Executive. This release includes, without implication of limitation, the complete waiver and release of all Claims arising in connection with Executives employment with and/or service as an officer and/or director of the Company, or Executives retirement and/or separation from employment with and/or service as an officer and/or director of the Company; provided, however, that notwithstanding the foregoing, the Company does not release Executive from any civil claims based on any acts and/or omissions that satisfy the elements of a criminal offense or claims arising out of any deliberate misconduct by Executive that resulted in injury to the Company (provided that the Company hereby represents that it knows of no such claims) nor does the Company release Executive with respect to any clawback of the Executives compensation to the extent required by the Sarbanes-Oxley Act (SOX), the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank) or any other applicable law. |
6. Restrictive Covenants . Executive hereby reaffirms his obligations pursuant to the Employee Non-Disclosure and Developments Agreement, dated July 9, 2001, and the Noncompetition and Non-Solicitation Agreement dated July 9, 2001, both of which are in effect regardless of whether the Executive enters into this Retiremenent Agreement, and Executive acknowledges and agrees that he will continue to abide by the obligations set forth in Section 5 of the Severance Plan, including those obligations with respect to Confidentiality, Confidential Information, Return of Property, Noncompetition and Nonsolicitation (which continue for 24 months from the Retirement Date (the Post-employment Restricted Period)), Cooperation and Non-disparagement (collectively, Restrictive Covenants). In turn, the Company agrees that it will direct its current officers and directors that none of them shall make or cause to be made, directly or indirectly, any statement to any person criticizing or disparaging Executive. The Restrictive Covenants are incorporated by reference herein as material terms of this Retirement Agreement. Executive further acknowledges and agrees that, among other things, the Restrictive Covenants will bar Executive from engaging in any business activities with respect to wearable infusion pumps during the Post-employment Restricted Period. In the event of a final determination by a court of competent jurisdiction that Executive has materially breached any of the Restrictive Covenants, in addition to any other legal or equitable remedies it may have for such breach, the Company shall have the right to terminate or suspend its Severance Benefits to Executive. The termination or suspension of such Severance Benefits in such event will not affect Executives continuing obligations under this Retirement Agreement.
6
7. Communications Concerning Executives Retirement . After consultation with Executive, the Board will issue a press release about Executives retirement (the Announcement ), on or around the Retirement Date which is in all respects consistent with this Agreement. Executive agrees not to communicate with any person or entity about his departure prior to the Announcement provided Executive may communicate with his immediate family and legal and professional financial advisors provided such persons first agree to keep the information strictly confidential. Executive further agrees that, directly or indirectly, he will not make any statement or authorize any other person or entity to make a statement that is inconsistent with the Announcement after it is made, and the Company agrees that it will direct its current officers and directors that none of them shall directly or indirectly make any statement or authorize any other person or entity to make a statement that is inconsistent with the Announcement after it is made. Nothing in this Agreement shall be interpreted to affect any persons obligation to testify truthfully in a legal proceeding.
8. Advice of Counsel . This Retirement Agreement is a legally binding document and the Companys and Executives signatures will commit each to its terms. Executive acknowledges that he has been advised to discuss all aspects of this Retirement Agreement with his attorney, that he has, in fact, consulted with counsel, that he has carefully read and fully understands all of the provisions of this Retirement Agreement and that Executive is voluntarily entering into this Retirement Agreement.
9. Time for Consideration; Effective Date . To accept this Retirement Agreement, Executive must return a signed original of this Retirement Agreement so that it is received by the Companys Lead Independent Director on or before 6:00 p.m. on September 12, 2014. This Retirement Agreement shall become effective upon execution by both parties (the Effective Date ).
10. Benefits and Burdens . This Agreement shall inure to the benefit of and be binding upon the Company and Executive, their respective successors, executors, administrators, heirs and permitted assigns. In the event of Executives death after the Retirement Date but prior to the provision by the Company of all of the Severance Benefits due Executive under this Agreement, the Company shall continue to provide such Severance Benefits to Executives beneficiary designated in writing to the Company prior to his death (or to his estate, if Executive fails to make such designation).
11. Enforceability . Executive acknowledges that, if any portion or provision of this Retirement Agreement, including any part of the Restrictive Covenants, shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision shall be valid and enforceable to the fullest extent permitted by law.
12. Entire Agreement . This Retirement Agreement constitutes the entire agreement between Executive and the Company concerning Executives relationship with the Company and supersedes and replaces any and all prior agreements and understandings between the Parties concerning the Executives relationship with the Company including, without limitation, any employment agreement, provided, the Restricted Covenants as set forth in Section 5 of the Severance Plan and the Equity Documents, as modified by Section 3 of this Retirement
7
Agreement, shall continue to be in full force and effect. In addition, Sections 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 (provided that no such amendment or termination shall affect the obligations of the Company to make the payments due to Executive hereunder subject to the terms of this Agreement), 18 and 19 of the Severance Plan shall also survive.
13. Waiver . No waiver of any provision of this Retirement Agreement, including the Restrictive Covenants, which are incorporated by reference into this Retirement Agreement, shall be effective unless made in writing and signed by the waiving party. The failure of either Party to require the performance of any term or obligation of this Retirement Agreement or the waiver by either Party of any breach of this Retirement Agreement, including any part of the Restrictive Covenants, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.
14. Taxes . The Company shall undertake to make deductions, withholdings and tax reports with respect to payments and benefits under this Retirement Agreement and in connection with other compensation matters to the extent that it reasonably and in good faith determines that it is required to make such deductions, withholdings and tax reports. Nothing in this Retirement Agreement shall be construed to require the Company to make any payments to compensate Executive for any adverse tax effect associated with any payments or benefits made to Executive pursuant to this Retirement Agreement.
15. Governing Law; Interpretation . This Retirement Agreement shall be interpreted and enforced under the laws of the Commonwealth of Massachusetts without regard to conflict of law principles. In the event of any dispute, this Retirement Agreement is intended by the parties to be construed as a whole, to be interpreted in accordance with its fair meaning, and not to be construed strictly for or against either Party or the drafter of all or any portion of this Retirement Agreement.
16. Counterparts . This Retirement Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original, but all of which together shall constitute one and the same document. Facsimile and PDF signatures shall be deemed to be of equal force and effect as originals.
8
IN WITNESS WHEREOF , the Parties, intending to be legally bound, have executed this Retirement Agreement on the date(s) indicated below.
INSULET CORPORATION
/s/ Daniel Levangie |
September 16, 2014 |
|||
Daniel Levangie | Date | |||
Lead Director |
I HAVE READ THIS RETIREMENT AGREEMENT THOROUGHLY, UNDERSTAND ITS TERMS AND HAVE SIGNED IT KNOWINGLY AND VOLUNTARILY. I UNDERSTAND THAT THIS RETIREMENT AGREEMENT IS A LEGAL DOCUMENT.
/s/ Duane DeSisto |
September 16, 2014 |
|||
Duane DeSisto | Date |
9
Exhibit 10.2
EMPLOYMENT AGREEMENT
This Employment Agreement (Agreement) is made as of the 16 th day of September, 2014, between Insulet Corporation, a Delaware corporation (the Company), and Patrick J. Sullivan (the Executive).
WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on September 17, 2014 (the Commencement Date) on the terms contained herein; and
WHEREAS, the Company maintains the Amended and Restated Executive Severance Plan adopted as of May 8, 2008, and amended as of November 14, 2008 and December, 2010 (the Severance Plan), which is incorporated herein by reference.
WHEREAS, unless otherwise defined herein, capitalized terms shall have the same meaning as in the Severance Plan;
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
1. Employment .
(a) Term . The Company hereby employs the Executive, and the Executive hereby accepts such employment until his employment under this Agreement is terminated by either party in accordance with the terms hereof. The Executives employment with the Company shall be at will, meaning that the Executives employment may be terminated by the Company or the Executive at any time.
(b) Position and Duties . The Executive shall serve as the President and Chief Executive Officer of the Company (CEO) and shall report solely to the Board of Directors of the Company (the Board). The Executive shall have all authorities customary for a CEO of a corporation of the Companys size and nature. So long as Executive serves as CEO he shall serve as a member of the Board. The Executive shall be principally located at the Companys headquarters. The Executive shall devote his full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may (to the extent not inconsistent with his duties at the Company): (i) serve on the boards of Perkin Elmer and Theragenics; (ii) hold the position of Managing Director of Aton Partners; (iii) engage in educational, charitable and civic activities; (iv) accept and fulfill a reasonable number of speaking engagements; and (v) manage his personal investments and affairs.
2. Compensation and Related Matters .
(a) Base Salary . The Executives initial annual base salary shall be $650,000 per year. The Executives base salary shall be reviewed at least annually by the Board or the Compensation Committee of the Board for increase only and is not subject to decrease at any time or for any reason (including for the purpose of determining Termination Benefits). The
base salary in effect at any given time is referred to herein as Base Salary. The Base Salary shall be payable in a manner that is consistent with the Companys usual payroll practices for senior executives.
(b) Bonus . The Executive shall be eligible to receive cash bonus as determined by the Board or the Compensation Committee from time to time. The Executives target annual cash bonus shall be 100 percent of his Base Salary with the actual earned amount to be based on performance as set forth in the Companys annual bonus plan to be approved by the Board or the Compensation Committee. Except as otherwise provided herein with respect to a Terminating Event, to earn a bonus the Executive must be employed by the Company on the day such bonus is paid. For the 2014 calendar year, Executive shall be eligible for a pro-rata bonus based on the Companys existing bonus plan for executives.
(c) Expenses . The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.
(d) Other Benefits . The Executive shall be eligible to participate in or receive benefits under the Companys employee benefit plans in effect from time to time, subject to the terms and conditions of such plans.
(e) Vacation . The Executive shall be entitled to accrue up to four weeks of paid vacation each year, which shall be accrued ratably. The Executive shall also be entitled to all paid holidays given by the Company to its executives.
(f) Stock Options . Subject to the Executive commencing employment with the Company on the Commencement Date, on October 1, 2014 (the Grant Date) the Executive will be granted an option to purchase shares of the Companys Common Stock (Initial Option Grant). The number of option shares in the Initial Option Grant shall be determined by dividing (i) $11,000,000 by (ii) 59.83% of the closing price of the Companys Common Stock on the Grant Date. The exercise price per share will be the closing price of the Companys Common Stock on the Grant Date. The Initial Option Grant will be subject to the terms and conditions applicable to options granted under the Companys Amended and Restated 2007 Stock Option and Incentive Plan (the Plan), as described in the Plan and the applicable stock option agreement to be signed by the Company and the Executive and which shall include the following terms:
(i) 25% of the Initial Option Grant shares shall vest and become exercisable on December 31, 2014 (the Initial Vesting Date);
(ii) the remaining 75% of the Initial Option Grant shares shall vest and become exercisable ratably in twelve (12) equal installments over the next three years on a quarterly basis after the Initial Vesting Date;
(iii) the Initial Option Grant shall be transferable to estate planning vehicles to the extent permitted under the Plan; and
(iv) the terms described in Sections 2(h) and 4(b) of this Agreement.
(g) Additional Equity Grants . The Executive shall be eligible for additional annual equity grants as determined by the Compensation Committee in its sole discretion, with the first such grants (if any) to be made in the first quarter of 2015.
(h) Terms of Equity Grants . To the extent consistent with this Agreement, all equity grants shall be subject to the Plan, as may be amended, and the applicable stock option or restricted stock unit agreements including with respect to clawbacks and vesting; provided, however, that (i) no amendment to the Plan shall have an adverse effect on the terms of outstanding awards, and (ii) all timebased equity grants shall be fully vested and any performance based grants will vest as if the applicable performance metric has been achieved at target (but not exceeded) upon a termination of the Executives employment by the Company without Cause or a resignation by the Executive for Good Reason, in either case if such Terminating Event occurs within twenty four (24) months following a Change in Control.
3. Termination . During the Term, the Executives employment hereunder may be terminated without any breach of this Agreement under the following circumstances:
(a) Death . The Executives employment hereunder shall terminate upon his death.
(b) Disability . The Company may terminate the Executives employment if he is disabled and unable to perform the essential functions of the Executives then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executives then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executives guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Companys determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executives rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq . and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.
(c) Termination by Company for Cause . The Company may terminate the Executives employment hereunder for Cause by providing a Notice of Termination within thirty days of the Boards knowledge of the circumstances that provide the basis for a Cause termination. For purposes of this Agreement, Cause shall have the meaning given to such term in the Severance Plan, provided, Section 2(b)(iv) of the Severance Plan shall be deleted in its entirety and replaced with the following: (iv) a material breach by the Covered Executive of any of the provisions contained in Section 5 of this Plan which, if curable, has continued for more than 30 days following written notice of such breach from the Company.
(d) Termination Without Cause . The Company may terminate the Executives employment hereunder at any time without Cause. Any termination by the Company of the Executives employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.
(e) Termination by the Executive . The Executive may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, Good Reason shall have the meaning given such term in the Severance Plan, provided that: (i) the following shall be added as Section 2(e)(iv) of the Severance Plan: any other action or inaction by the Company that constitutes a material breach of any contractual obligations to the Covered Executive; and (ii) the last sentence of Section 2(e) of the Severance Plan shall be deleted in its entirety and replaced with the following: For purposes of Section 2(e)(i), a change in the reporting relationship or a title described in an employment agreement will be sufficient to constitute a material diminution of responsibilities, authority or duties.
(f) Notice of Termination . Except for termination as specified in Section 3(a), any termination of the Executives employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a Notice of Termination shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon. This Section 3(f) shall apply in lieu of Section 10(a) of the Severance Plan.
(g) Date of Termination . Date of Termination shall mean: (i) if the Executives employment is terminated by his death, the date of his death; (ii) if the Executives employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executives employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executives employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executives employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement. This Section 3(g) shall apply in lieu of Section 10(b) of the Severance Plan.
4. Compensation Upon Termination .
(a) Termination Generally . If the Executives employment with the Company is terminated for Cause, death, or disability or by the Executive without Good Reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements
(subject to, and in accordance with, Section 2(c) of this Agreement) and unused vacation that accrued through the Date of Termination on or before the time required by law but in no event more than 30 days after the Executives Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans. Upon any termination of the Executives employment, Executive shall remain subject to Sections 5, 6 and 7 of the Severance Plan as modified by Section 6 of this Agreement, and the Executive shall not be eligible to receive any additional benefits (if any) in accordance with then-applicable terms of any plan, program, agreement, governance document or other arrangement of the Company or its affiliates (the Company Arrangements) that are duplicative of the any of the terms of this Agreement.
(b) Accelerated Equity and Exercise Period . If (A) the Executive either (i) is terminated by the Company without Cause, (ii) resigns for Good Reason, or (iii) after the Executive has assisted in developing a CEO succession plan and the Board has approved such plan, resigns without Good Reason and, as of the Date of Termination, the Executive has not engaged in any acts or omissions that could provide the Company with a basis for terminating the Executives employment for Cause, and (B) the Date of Termination (as defined below) occurs on or after three (3) years after the Commencement Date, then, subject to the Executive entering a Release timely provided to him, all of the Executives then time-based unvested options and other time-based unvested stock-based awards shall become fully vested and exercisable (Accelerated Vesting) and such vested options will remain fully exercisable until the earlier of (i) three years from the Date of Termination and (ii) the original expiration date that would apply if employment had continued (Extended Exercise Period), provided, in the event (i) the Executive breaches a Restrictive Covenant (as defined below) that, if curable, continues for more than 30 days following written notice of such breach from the Company, or (ii) a forfeiture condition required by law occurs, the Accelerated Vesting and Extended Exercise Period shall not apply and such options shall immediately terminate. A Release shall not (i) require the Executive to waive his rights under this Agreement, (ii) require the Executive to waive his vested benefits, if any, under any Company Arrangement that is not duplicative with the terms of this Agreement, or (iii) impose any additional post-employment obligations on the Executive, provided the Executive shall be required to reaffirm the Restrictive Covenants.
(c) Terminating Event . If the Executive experiences a Terminating Event, the Executive shall be entitled to the termination benefits set forth in Section 3 of the Severance Plan, subject to all of the terms and conditions of the Severance Plan, provided Section 3(a) of the Severance Plan shall be deleted in its entirety and shall be replaced with the following: (a) pay the Covered Executive an amount equal to the sum of two (2) times the sum of (x) the Executives annualized Base Salary as of the Terminating Event plus (y) the higher of his target annual bonus for the year in which the Terminating Event occurs or his annual bonus for the previous year. Such amount shall be paid, subject to Section 9, (A) in the event the Terminating Event occurs prior to a Change in Control, then in substantially equal installments in accordance with the Companys payroll practice over 24 months, beginning on the first payroll date that occurs 30 days after the Terminating Event, or (B) in the event the Terminating Event occurs on or after a Change in Control, then in a single lump sum payment on the first business day that occurs 30 days after the Terminating Event. In addition, the Executive shall receive any unpaid bonus for any calendar year ending prior to the Terminating Event, and a Pro-Rata Bonus. For
purposes of this Agreement, Terminating Event shall have the meaning given to such term in the Severance Plan, provided, in Section 2(h)(ii) of the Severance Plan during the 24-month period following the occurrence of a Change in Control shall be deleted and the remainder of the provision shall be unaffected.
5. Section 409A .
(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executives separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a specified employee within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executives separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executives separation from service, or (B) the Executives death.
(b) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.
(c) To the extent that any payment or benefit described in this Agreement constitutes non-qualified deferred compensation under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executives termination of employment, then such payments or benefits shall be payable only upon the Executives separation from service. However, the Executive shall not have any duties after his Date of Termination that are inconsistent with his having a separation from service on his Date of Termination. The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).
(d) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.
(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.
6. Restrictive Covenants . The Executive acknowledges and agrees that Section 5(a)-(g) of the Severance Plan with respect to Confidentiality, Confidential Information, Documents, Records, etc, Noncompetition and Nonsolicitation, Litigation and Regulatory Cooperation, Non-Disparagement (collectively the Restrictive Covenants) and Injunction are incorporated by reference into and are material terms of this Agreement, provided, however, that no violation of the Restrictive Covenants shall occur (A) by reason of any disclosure made (i) to the extent necessary to comply with any law, subpoena, governmental order or request or direction from a regulatory or self-regulatory organization with apparent jurisdiction, (ii) in any arbitration or proceeding to defend or enforce the Executives rights, or (iii) in confidence to an attorney or financial advisor for the purpose of obtaining professional advice, or (B) by reason of the Executive retaining copies of documents pertaining to his personal entitlements, benefits, obligations and tax liabilities. The Executive will also execute the Companys standard form of Inventions Agreement connection with his Employment.
7. Arbitration of Disputes . Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise arising out of the Executives employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (AAA) in Boston, Massachusetts in accordance with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. In the event that any person or entity other than the Executive or the Company may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entitys agreement. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section 7 shall be specifically enforceable. Notwithstanding the foregoing, this Section 7 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 7.
8. Consent to Jurisdiction . To the extent that any court action is permitted consistent with or to enforce Section 7 of this Agreement, the parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.
9. Integration . This Agreement, and the Severance Plan as modified herein, constitute the entire agreement between the parties with respect to the subject matter hereof and
supersedes all prior agreements between the parties concerning such subject matter. In the event of any inconsistency between the provisions of this Agreement and the provisions of any other Company Arrangement, the provisions of this Agreement shall control.
10. Withholding . All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.
11. Successor to the Executive . This Agreement shall inure to the benefit of and be enforceable by the Executives personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executives death after his termination of employment but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue such payments to the Executives beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).
12. Enforceability . If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.
13. Survival . The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executives employment to the extent necessary to effectuate the terms contained herein.
14. Waiver . No waiver of any provision hereof shall be effective unless made in a writing that specifically identifies the provision being waived and is signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.
15. Notices . Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.
16. Amendment . This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company that specifically identifies the provisions being amended or modified.
17. Indemnity . The Company shall, to the full extent permitted by law and the Companys bylaws , indemnify and hold the Executive harmless from and against any liability, damage, claim or expense incurred by reason of any act performed or omitted to be performed by him in connection with his employment with, or services for, the Company, such indemnification
to include, without limitation, the advance payment of attorneys fees and other expenses reasonably incurred by the Executive in connection with defending, or otherwise resolving, any claim based on any such act or omission. The Executive shall be covered under any directors and officers liability insurance policies maintained by or for officers or directors of the Company on no less favorable a basis than that applying to any of the Companys officers or directors in general.
18. Governing Law . This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.
19. Counterparts . This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document. Signatures delivered via facsimile or email shall be effective for all purposes.
20. Successor to Company . The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.
21. Gender Neutral . Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.
IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.
INSULET CORPORATION | ||
By: |
/s/ Daniel Levangie |
|
Its: |
Lead Director |
|
EXECUTIVE | ||
/s/ Patrick J. Sullivan |
||
Patrick J. Sullivan |
Exhibit 99.1
INSULET CORPORATION APPOINTS PATRICK J. SULLIVAN AS
PRESIDENT AND CHIEF EXECUTIVE OFFICER
Duane DeSisto Retires from the Company after 13 Years
BILLERICA, MA September 16, 2014 Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced that Patrick J. Sullivan has been appointed President and Chief Executive Officer, and Director effective immediately. Mr. Sullivan succeeds Duane DeSisto, who is retiring after 13 years at the Company. Mr. DeSisto will be available to the Company as a consultant through the end of 2014 to assist with an effective leadership transition.
Mr. Sullivan brings more than 30 years of executive leadership experience to Insulet. As Chairman, President and CEO of Cytyc Corporation from 1994 to 2007, Cytyc became one of the most successful medical device and diagnostics companies as revenues increased from $4 million to more than $750 million through a combination of organic growth and strategic acquisitions. Following the acquisition of Cytyc by Hologic, Inc. in 2007, Mr. Sullivan served as Executive Chairman of Hologic, while leading a series of early stage medical device and in vitro diagnostics ventures with Constitution Medical Investors and Aton Partners. He continues to serve as a director of PerkinElmer, Inc.
Patrick is a respected industry veteran with an exceptional track record of growing organizations, driving corporate development and successfully building product and customer pipelines to create value for shareholders, said Dan Levangie, Lead Director of Insulet. Pats insight and experience will be instrumental as the Company continues to build on its solid foundation and strong growth prospects. We are excited to add Pat to the team and look forward to his leadership.
Mr. DeSisto said, I am grateful and deeply honored to have had the opportunity to lead Insulet over the past thirteen years. While I am very proud of all that the Company has achieved, I am most proud in knowing that the OmniPod has given the freedom and simplicity of tubeless pumping to more than 60,000 people living with diabetes. We have passed many important milestones over the years, and I am delighted that we have been able to attract a proven corporate leader of Pats ability to lead Insulet through its next phase of growth and development. On a personal note, I would like to thank the talented Insulet team for all that we achieved together and to wish everyone at Insulet the very best for the future.
Mr. Levangie added, On behalf of the entire Board of Directors and everyone at Insulet, we thank Duane for his enormous contribution to the Company. Under his leadership, Insulet has built a strong foundation for continued growth, and the results of Duanes vision and commitment to this business will continue to be a driver of future success. He has earned the respect of his colleagues at Insulet and across the industry as a whole, and we wish him the very best in his future endeavors.
I am very excited to be joining Insulet and I look forward to working with the Board and outstanding leadership team to further establish the Company as a leader in the management of diabetes, said Mr. Sullivan. Insulet has world-class technology that helps a large and growing population of people live their lives without sacrificing freedom. I am confident that Insulet has a valuable opportunity to continue to work with healthcare providers to improve the lives of the millions of people around the world living with diabetes and to create significant value for our shareholders.
1
Guidance
The Company reiterates its estimate of revenue to be in the range of $73 to $77 million for the third quarter of 2014 and $290 to $300 million for the year ending December 31, 2014. Additionally, the Company expects to record a charge of approximately $8 to $10 million in the third quarter of 2014 to compensation expense, primarily related to the non-cash acceleration of certain equity awards and an additional charge of approximately $3 million in the fourth quarter of 2014, primarily related to non-cash stock based compensation expense.
About Patrick J. Sullivan
Mr. Sullivan joins Insulet Corporation having most recently served as Managing Director of Aton Partners. Prior to that, Mr. Sullivan served as Chairman and CEO of Constitution Medical Investors from 2008 to 2013. Mr. Sullivan served as Executive Chairman of Hologic from its merger with Cytyc Corporation in October 2007 until May 2008, having previously served Cytyc as Chairman, President and Chief Executive Officer. Mr. Sullivan first joined Cytyc in 1991 and was employed prior to that in marketing roles of increasing responsibility at Abbott Laboratories, a diversified healthcare company, and as a consultant with McKinsey & Company, an international management consulting firm. Mr. Sullivan serves as a director of PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment. Mr. Sullivan holds a Bachelor of Science degree, with Distinction, from the United States Naval Academy and a Master of Business Administration degree, with Distinction, from Harvard Business School.
Inducement Grant
Mr. Sullivan and the Company have entered into an employment agreement that provides in part that he will be issued on October 1, 2014 a stock option to purchase that number of shares of the Companys common stock equal to $11,000,000 divided by the product of 59.83% multiplied by the closing price of the Companys common stock on the date of the grant. The exercise price of this stock option will be the closing price of the Companys common stock on the date of the grant. This stock option qualifies as an employment inducement grant and is not being issued under an equity compensation plan approved by the Companys stockholders.
About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and fully-automated cannula insertion. Insulets subsidiary, Neighborhood Diabetes, is a leading distributor for diabetes products and supplies, delivered through a high touch customer service model. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod, visit our customer blog, Suite D: http://suited.myomnipod.com. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts. For more information, please visit: http://www.myomnipod.com.
Forward-Looking Statement
This press release contains forward-looking statements concerning Insulets expectations, anticipations, intentions, beliefs or strategies regarding the future, including those related to its estimated revenue for the 2014 third quarter and full year and the expected compensation charge in the third and fourth quarters of 2014. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the Companys dependence on its principal product, the OmniPod System; Insulets ability to reduce production costs and increase customer orders and manufacturing volumes; adverse changes in general economic conditions; impact of healthcare reform laws; Insulets ability to raise additional funds in the future on acceptable terms or at all; potential supply problems or price fluctuations with sole source or third-party suppliers on which Insulet is dependent; the potential
2
establishment of a competitive bid program for conventional insulin pumps; failure by Insulet to retain supplier pricing discounts and achieve satisfactory gross margins; failure by Insulet to retain key supplier and payor partners; international business risks; Insulets inability to secure and retain adequate coverage or reimbursement from third-party payors for the OmniPod System and potential adverse changes in reimbursement rates or policies relating to the OmniPod System; failure to retain key payor partners and their members; failure to retain and manage successfully Neighborhood Diabetes Medicare and Medicaid business; potential adverse effects resulting from competition with competitors; technological change and product innovation adversely affecting the Companys business; potential termination of Insulets license to incorporate a blood glucose meter into the OmniPod System or its inability to enter into new license agreements; Insulets ability to protect its intellectual property and other proprietary rights; conflicts with the intellectual property of third parties, including claims that Insulets current or future products infringe or misappropriate the proprietary rights of others; adverse regulatory or legal actions relating to the OmniPod System; failure of Insulets contract manufacturers or component suppliers to comply with FDAs quality system regulations, the potential violation of federal or state laws prohibiting kickbacks or protecting the confidentiality of patient health information, or any challenge to or investigation into Insulets practices under these laws; product liability lawsuits that may be brought against Insulet; reduced retention rates of our customer base; unfavorable results of clinical studies relating to the OmniPod System or the products of Insulets competitors; potential future publication of articles or announcement of positions by diabetes associations or other organizations that are unfavorable to the OmniPod System; the concentration of substantially all of Insulets operations at a single location in China and substantially all of Insulets inventory at a single location in Massachusetts; Insulets ability to attract and retain personnel; Insulets ability to manage its growth; fluctuations in quarterly results of operations; risks associated with potential future acquisitions or investments in new businesses; Insulets ability to generate sufficient cash to service all of its indebtedness; the expansion of Insulets distribution network; Insulets ability to successfully maintain effective internal control over financial reporting; the volatility of Insulets common stock; risks related to future sales of its common stock or the conversion of any of the 2% Convertible Senior Notes due June 15, 2019; potential limitations on Insulets ability to use its net operating loss carryforwards; anti-takeover provisions in its organizational documents; disruptions caused by the change in the Companys Chief Executive Officer; and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 28, 2014 in the section entitled Risk Factors, and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
Investor Relations Contact: |
ir@insulet.com |
877-PODD-IR1 (877-763-3471) |
3